Advisor Group’s Viking Therapeutics VKTX Stock Holding History

Advisor Group’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$230K	Buy	28,683 +4,595	+19%	+$33.5K	﹤0.01%	2287
2019 Q3	$166K	Buy	24,088 +1,971	+9%	+$14.6K	﹤0.01%	2458
2019 Q2	$183K	Buy	22,117 +2,553	+13%	+$21.8K	﹤0.01%	2382
2019 Q1	$195K	Buy	19,564 +3,608	+23%	+$30.2K	﹤0.01%	2302
2018 Q4	$122K	Buy	15,956 +6,037	+61%	+$72.2K	﹤0.01%	2485
2018 Q3	$173K	Buy	9,919 +5,609	+130%	+$66.7K	﹤0.01%	2294
2018 Q2	$41K	Buy	+4,310	New	+$28.7K	﹤0.01%	3260
2017 Q4	–	Sell	-500	Closed	-$1K	–	5073
2017 Q3	$1K	Hold	500	–	–	﹤0.01%	4729
2017 Q2	$1K	Hold	500	–	–	﹤0.01%	4682
2017 Q1	$1K	Hold	500	–	–	﹤0.01%	4590
2016 Q4	$1K	Hold	500	–	–	﹤0.01%	4407
2016 Q3	$1K	Buy	+500	New	+$662	﹤0.01%	4363

Other funds holding VKTX

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Advisor Group's VKTX Position: Q4 2019 in Review

Advisor Group increased its Viking Therapeutics (VKTX) stake by 19% in Q4 2019, buying an estimated $33.5K and bringing the position to 28,683 shares worth $230K. The position accounts for ﹤0.01% of the portfolio, ranked #2287.

Advisor Group first reported a position in VKTX in Q3 2016 and has held it in 12 quarters since. 143 funds tracked by Wall St. Rank hold VKTX as of Q4 2019.

Advisor Group held 28,683 shares of Viking Therapeutics worth $230K as of Q4 2019.
Advisor Group bought 4,595 Viking Therapeutics shares in Q4 2019, an estimated $33.5K.
Viking Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #2287 holding.
Advisor Group first reported a position in Viking Therapeutics in Q3 2016 and has held it in 12 quarters since.
143 funds tracked by Wall St. Rank held Viking Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.